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Callyspongisines A–D: bromopyrrole alkaloids from 
an Australian marine sponge, Callyspongia sp. 
Fabien Plisson,a Pritesh Prasad,a Xue Xiao,a Andrew M. Piggott,a  
Xiao-cong Huang,a Zeinab Khalila and Robert J. Capona* 
An extract of the Great Australian Bight marine sponge Callyspongia sp. (CMB-01152) 
displayed inhibitory activity against the neurodegenerative disease kinase targets casein kinase 
1 (CK1), cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3 (GSK3β). 
Chemical investigation, employing HPLC-DAD-MS single ion extraction protocols, facilitated 
identification of the new bromopyrrole alkaloids, callyspongisines A–D (1–4), and two known 
co-metabolites, hymenialdisine (5) and 2-bromoaldisine (6). Structure elucidation of 1–6 was 
supported by detailed spectroscopic analysis and chemical interconversion, as well as 
biosynthetic and synthetic considerations. Callyspongisine A (1) is only the second reported 
example of a natural imino-oxazoline, and the first to feature a spiro heterocyclic framework, 
while callyspongisines B–D (2–4) were speculated to be storage and handling artefacts of 1. 
The kinase inhibitory activity detected in Callyspongia sp. (CMB-01152) was attributed to 5. 
 
Introduction 
Natural products can be viewed as bioactive chemicals 
produced by organisms, and optimized by evolution, to deliver 
a survival advantage. Knowledge of natural product chemistry, 
ecology and biology has inspired generations of researchers, 
informing our understanding of the natural world, and inspiring 
the development of many of the most successful medicines. 
Notwithstanding past successes, there remains an urgent need 
to continue natural products discovery, to deliver new and 
improved therapeutics capable of treating a broad array of 
existing and emerging diseases. For example, the very fact that 
healthcare programs successfully extend life has the alarming 
corollary of increasing the incidence of neurodegenerative 
disorders (NDs) in an aging population. Patients suffering from 
the archetypal ND, Alzheimer’s disease (AD), experience 
severe and irreversible deterioration of cognitive ability and 
loss of quality of life, driven by a highly distinctive amyloid 
and tau brain pathology. Existing wisdom has amyloid 
pathology caused by the protease β-secretase (BACE) 
abnormally processing the essential neuronal transmembrane 
amyloid precursor protein (APP) to generate amyloid (Aβ  
plaques. Likewise, tau pathology is believed to be caused by a 
host of kinases, including casein kinase 1 (CK1), cyclin-
dependent kinase 5 (CDK5) and glycogen synthase kinase 3 
(GSK3β), abnormally hyperphosphorylating the highly soluble 
microtubule-associated tau protein to generate neurofibrillary 
tangles (NFT).1 The development of clinically useful treatments 
for AD (and other NDs) has included a search for safe, potent 
and selective inhibitors of amyloid and tau pathology. 
In collaboration with the Spanish pharmaceutical company 
Noscira, we screened a library of ~2,600 southern Australian 
and Antarctic marine organisms to successfully detect extracts 
that inhibited BACE (27, 1%), CK1 (44, 1.7%), CDK5 (26, 
1%) and GSK3β (69, 2.6%), and that contained rare and new 
natural product scaffolds. A particularly promising extract, 
from a Great Australian Bight marine sponge Callyspongia sp. 
(CMB-01152), displayed inhibitory activity against all three 
kinases, with preliminary chemical profiling (HPLC-DAD-MS 
and 1H NMR) indicating the presence of brominated alkaloids.  
 
Fig. 1. HPLC-DAD-MS analysis of Callyspongia sp. (CMB-01152) crude extract 
showing HPLC-DAD trace at 254 nm and extracted ion mass chromatograms 
corresponding to quasi-molecular ions for 1, 2, 5, 6 and 3. 
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Results and Discussion 
A portion of the aqueous EtOH extract of Callyspongia sp. 
(CMB-01152) was decanted, concentrated in vacuo and 
subjected to solvent partitioning and trituration. Analytical 
HPLC-DAD-MS analysis (Fig. 1) revealed two major products 
(5 and 6), while careful analysis of the very minor co-
metabolites (utilizing single ion extraction protocols) detected 
four additional brominated co-metabolites (1–4). Subsequent 
semi-preparative reversed-phase HPLC fractionation yielded 
the new minor bromopyrrole alkaloids, callyspongisines A (1) 
and C–D (3–4), and the known major bromopyrrole alkaloids, 
hymenialdisine (5)2 and 2-bromoaldisine (6)3 (Fig. 2). Although 
callyspongisine B (2) was only detected in the crude extract at 
levels that precluded isolation and detailed spectroscopic 
analysis, hydrolysis of a portion of 1 yielded a sufficient 
quantity of 2 to permit assignment of the structure, as shown in 
Fig. 2. The known bromopyrroles 5 and 6 were identified by 
detailed spectroscopic analysis with comparison to literature 
data,2-3 while the structure elucidation of 1–4 is outlined below. 
 
Fig. 2. Callyspongia sp. (CMB-01152) chemistry 
HRESI(–)MS analysis of 1 revealed a quasi-molecular ion 
[M-H]– consistent with the molecular formula C12H14BrN5O5S 
(∆mmu –1.5), while analysis of the NMR (DMSO-d6) data 
(Table 1) permitted assembly of structure fragments A, B and C 
(Fig. 3). Fragment A (N-1 to C-10) was identified as a 2-
bromopyrrole fused to a 7-membered lactam, with the 2-bromo 
regiochemistry supported by comparison of NMR chemical 
shifts in 1 (δH 6.13, s, H-3; δC 110.5, C-3) with those for the 
known 2-bromopyrrole co-metabolites hymenialdisine (5) (δH 
6.63, s, H-3; δC 111.2, C-3), 2-bromoaldisine (6) (δH 6.68, s, H-
3; δC 113.3, C-3) and spongiacidin D (7) (δH 6.53, s, H-3; δC 
111.7, C-3),4 and the known 3-bromopyrrole analogues 
debromostevensine (8) (δH 7.20, d, H-2; δC 123.0, C-2),
5 
debromohymenin (9) (δH 7.08, d, H-2; δC 122.1, C-2)
5 and 
spongiacidin B (10) (δH 7.28, H-2; δC 123.2, C-2)
4 (Fig. 4). 
Fragment B (N-15 to C-17, plus C-11) was identified as a 
taurinyl residue fused to an sp2 hybridized deshielded 
quaternary carbon (δC 181.0, C-11), with the latter more 
consistent with an imidazoline (e.g nagelamide X (11), δC 
179.1)6 than an amide (e.g mauritamide D (12), δC 158.8)
7 (Fig. 
4). The presence of a taurinyl moiety was further supported by 
comparison of NMR data with an array of known sponge 
taurinyl-2-aminoimidazoles (ESI Fig. S1 and Table S1). A 
diagnostic HMBC correlation from 15-NH to C-10 supported 
assembly of fragments A and B (Fig. 3), and necessitated that 
fragment C (CH2NO) be incorporated into 1 as a spiro 
heterocyclic moiety. The deshielded 13C NMR shift for C-10 in 
1 (δC 91.1) favoured substitution by oxygen (e.g. pemoline 
(13), δC 82.3, and indolmycin (14), δC 85.3),
 versus nitrogen 
(e.g. 5-phenyl-hydantoin (15)δC 61.2)
8 (Fig. 4). Diagnostic 
HMBC correlations from 14-NH2 to C-11 and from H-9 to C-
13 supported assembly of fragments A, B and C (Fig. 3). Thus 
callyspongisine A (1) was identified as the first example of a 
natural product bearing a spiro-imino-oxazoline moiety, and 
was assigned the structure as shown (Fig. 2). Further support 
for this assignment is outlined below. 
 
Fig. 3. Diagnostic 2D NMR correlations and structure fragments for 1–4 
HPLC-DAD-MS analysis of a sample of 1 (m/z 418 [M–H]–) 
stored for >12 months at –30 °C in DMSO revealed ~10% 
conversion to a less polar analogue 2 (m/z 419 [M–H]–) with a 
near identical UV-vis spectrum. HPLC-HRESI(–)MS analysis 
on this mixture established a molecular formula for 2 
(C12H13BrN4O6S, ∆mmu –0.6) indicative of a hydrolysis 
product of 1. Supportive of this hypothesis, a sample of 1 in 
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Fig. 4. Known model compounds 7–15 with key carbons highlighted 
0.5% TFA/MeOH maintained at 65 °C for 3 days was observed 
to undergo conversion to >60% 2, with a plausible mechanism 
for this transformation outlined in Fig. 5. Analysis of the NMR 
(DMSO-d6) data for 2 (Table 1 and Fig. 3) confirmed the 
presence of structure fragments A and B, while the absence of 
resonances associated with 14-NH2 and a more upfield 
resonance for C-13 (δC 165.2 in 2 vs. 172.3 in 1) indicated the 
presence of a spiro-oxazolone in place of the spiro-imino-
oxazoline in 1. These observations permitted assignment of the 
structure for callyspongisine B (2) as shown in Fig. 2.  
HRESI(+)MS analysis of the co-metabolites 3 and 4 revealed 
quasi-molecular and adduct ions consistent with the molecular 
formulae C13H17BrN2O4 ([M+H]
+, ∆mmu +0.2) and 
C11H13BrN2O4 ([M+Na]
+, ∆mmu –0.6) respectively. Analysis of 
NMR (DMSO-d6) data (Table 1) confirmed that 3–4 share 
fragment A in common with 1 (Fig. 3). This analysis also 
revealed that where 3 features 11-OEt (δH 1.06 and 3.30/3.45; 
δC 15.8 and 60.0) and 11-CO2Et (δH 1.17 and 4.11/4.15; δC 
14.2, 61.2 and 172.4) moieties, 4 features 11-OMe (δH 3.16; δC 
52.2) and 11-CO2Me (δH 3.67; δC 52.6 and 172.7) moieties. 
These considerations permitted assignment of structures to 
callyspongisines C (3) and D (4) as shown (Fig. 2).  
 
 
Fig. 5. Mechanism for hydrolysis of 1 to 2 
A plausible biosynthetic/chemical relationship linking 1–6 (Fig. 
6) invokes oxidative processing of ∆10,11 in 5 to yield 6 and the 
hydroxy acid precursor (i) that can later undergo conjugation 
with guanidine to yield a spiro-imino-oxazoline intermediate 
(ii), which in turn forms the taurinyl Schiff base 1. Supportive 
of the proposed guanidine conjugation step, treatment of 
mandelic acid ethyl ester with guanidine.HCl (2 eq.) and NaOH 
(2 eq.) delivered a high yield (82%) of the known imino-
oxazoline CNS stimulant pemoline (13). Subsequent efforts to 
form a pemoline-taurinyl Schiff base proved unsuccessful, 
presumably due to unfavourable keto-enol tautomerism. During 
long-term storage in EtOH we propose that 1 undergoes partial 
hydrolysis to 2, and (i) undergoes ethanolysis to 3. As 4 was 
only detected/isolated following HPLC (H2O/MeOH/TFA) 
fractionation we propose it is a methanolysis artefact of 3. In 
summary, we present callyspongisine A (1) as a natural 
product, and callyspongisines B–C (2–3) and callyspongisine D 
(4) as possible storage and isolation artefacts respectively.  
 
Fig. 6. Plausible biosynthetic/chemical relationship between 1–6 
Imino-oxazolines such as 1 are exceptionally rare in the natural 
products literature, with the only reported example being 
indolmycin (14), first reported in 1961 from Streptomyces 
albus9 and again in 1978 from Streptomyces griseus.10 
Renewed interest in the biological properties of 14 resurfaced 
recently, with 2001 and 2004 accounts of antibacterial activity 
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Table 1. 1H (600 MHz) and 13C (150 MHz) NMR data for callyspongisines A–D (1–4) in DMSO-d6 
Pos. callyspongisine A (1) callyspongisine B (2) callyspongisine C (3) callyspongisine D (4) 
 δH, mult (J in Hz) δC
 δH, mult (J in Hz) δC δH, mult (J in Hz) δC
C δH, mult (J in Hz) δC
C 
1-NH 12.71, s  12.43, s  12.25, s  12.29, s  
2  105.1  104.5  103.6  103.6 
3 6.13, s  110.5 5.86, s 110.1 6.13, s 112.6 6.13, s 112.4 
4  118.8  122.1  124.6  124.1 
5  127.3  126.5  125.4  125.7 
6  161.1  161.4  161.7  161.6 
7-NH 8.27, t (5.4)  8.10, dd (6.9, 2.8)  7.99, t (1.0)  8.00, s  
8 3.30A 36.1 
3.28A 
36.3 
a 3.28, m 
35.5 
a 3.26A, m  
35.5 
 b 3.15, ddd (7.7, 7.7, 1.0) b 3.16A, m 
9 
a 2.47, m 
36.6 
a 2.26, dd (14.8, 10.0) 
37.3 
a 2.31, dd (15.0, 7.7) 
34.7 
a 2.32, dd (15.0, 7.7) 
34.4 
b 2.39, m b 2.12, dd (14.8, 6.8) b 2.16, dd (15.0, 7.7) b 2.16, dd (15.0, 7.7) 
10  91.1  82.5  79.3  79.7 
11  181.0  181.8  172.4  172.7 
13  172.3  165.2     
14-NH2 
a 10.16, s         
b 9.74, s         
15-NH 10.34, t (5.4)  8.79, t (5.5)      
16 3.66, ddd (7.0, 7.0, 5.4) 41.1 3.50, m 39.6B     
17 
a 2.74, dt (13.0, 7.0) 
48.8 
a 2.68, m 
49.31 
    
b 2.67, dt (13.0, 7.0) b 2.59, m     
CO2CH2CH3 
    a 4.15, dq (14.3, 7.0) 
61.2 
  
    b 4.11, dq (14.3, 7.0)   
OCH2CH3 
    a 3.45, dq (14.2, 7.0) 
60.0 
  
    b 3.30A   
CO2CH2CH3     1.17, t (7.0) 14.2   
OCH2CH3     1.06, t (7.0)  15.8   
CO2CH3       3.67, s  52.6 
OCH3       3.16, s  52.2 
A Overlapped by H2O resonance. 
B Overlapped by DMSO resonance. C Assignments supported by 2D NMR correlations.  
against Helicobacter pylori11 and methicillin-resistant 
Staphylococcus aureus (MRSA),12 and an unpublished 2013 
observation in our laboratory that indolmycin exhibits growth 
inhibitory activity against the Mycobacterium tuberculosis 
surrogate Bacillus Calmette-Guérin (BCG). These observations 
prompted us to extend our biological evaluations to assess the 
kinase-inhibitory, cytotoxic and antibiotic properties of 1 and 
3–6. 
The kinase inhibitory activity detected in the Callyspongia sp. 
extract was attributed to the major metabolite hymenialdisine 
(5) (IC50 0.03 µM (CK1δ), 0.16 µM (CDK5/p25) and 0.07 µM 
(GSK-3β)), which is a well known kinase inhibitor.13 During 
cytotoxicity screening, 5 displayed moderate growth-inhibitory 
activity against human colon adenocarcinoma cell line SW620 
(IC50 3.1 µM) and epidermoid carcinoma cell line KB-3-1 (IC50 
2.0 µM), while all tested compounds were inactive (IC50 >30 
µM) against human multiform glioblastoma cell line SF-295 
and large cell lung cancer cell line NCI-H460. None of the 
tested compounds inhibited the efflux properties of the 
transmembrane transporter P-glycoprotein (P-gp) in the 
adriamycin and vinblastine selected multidrug-resistant cell 
lines, SW620 Ad300 and KB-V1, nor did they inhibit growth of 
the Gram-positive bacteria Staphylococcus aureus (ATCC 9144 
and ATCC 25923), Bacillus subtilis (ATCC 6051 and ATCC 
6633) and BCG (ATCC 35733), the Gram-negative bacteria 
Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa 
(ATCC 10145), or the fungus Candida albicans (ATCC 
90028). 
 
Conclusions 
In summary, during the course of our chemical investigation of 
the Great Australian Bight sponge Callyspongia sp. (CMB-
01152), we identified the major metabolites as the known 
bromopyrrole alkaloids hymenialdisine (5) and 2-bromoaldisine 
(6). Through the application of highly sensitive HPLC-DAD-
MS single ion extraction protocols, we extended these 
discoveries to detect and identify exceptionally minor 
callyspongisines 1–4. Callyspongisine A (1) is only the second 
reported example of a natural imino-oxazoline, and the first to 
feature a spiro heterocyclic framework, while callyspongisines 
B–D (2–4) were speculated to be storage and handling artefacts 
of 1. Structure elucidation of 1–6 was supported by detailed 
spectroscopic analysis and chemical interconversion, as well as 
biosynthetic and synthetic considerations. The potent kinase 
inhibitory activity detected in Callyspongia sp. (CMB-01152) 
was attributed to hymenialdisine (5), while the callyspongisines 
proved to be non-cytotoxic against a range of prokaryotic, 
eukaryotic and mammalian cell lines. 
Experimental section 
Collection 
The sponge material identified as Callyspongia sp. (UQ code: 
CMB-01152, Museum Victoria Registry No. MVF166266) was 
collected in January 1991 during a scientific expedition to the 
Great Australian Bight aboard the RV Franklin between 
Adelaide and Portland, SA. Freshly collected samples were 
frozen (–4 °C) for shipping to the laboratory, where they were 
thawed, catalogued, diced, and steeped in aqueous EtOH at –30 
°C for prolonged storage. 
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Extraction and isolation 
An aliquot (100 mL) of the aqueous EtOH extract of specimen 
CMB-01152 was decanted, concentrated in vacuo, and the 
residue (366.4 mg) partitioned between H2O and n-BuOH. The 
n-BuOH-soluble fraction was concentrated in vacuo (108.1 mg) 
and the residue further triturated into light petroleum (18.9 mg), 
CH2Cl2 (14.0 mg), and MeOH (74.3 mg) solubles. The H2O-
soluble fraction was concentrated in vacuo (258.3 mg) and the 
residue further triturated into MeOH (168.4 mg) and H2O (88.4 
mg) solubles. Kinase inhibition assays localized inhibitory 
activity in the CH2Cl2 and MeOH solubles. 
 
The CH2Cl2 solubles (14.0 mg) were subjected to HPLC 
fractionation (Agilent Zorbax Phenyl 5 µm, 150 × 4.6 mm 
analytical column, 1 mL/min, isocratic 0.01% TFA modifier, 
gradient elution from 90% H2O/MeCN to 100% MeCN over 18 
min, then a 4 min hold at 100% MeCN), to yield 2-
bromoaldisine (6) (tR = 9.2 min, 0.3 mg) and callyspongisine C 
(3) (tR = 13.0 min, 0.9 mg).  
 
A portion (37.1 mg) of the MeOH solubles derived from the n-
BuOH solubles was subjected to HPLC fractionation (Agilent 
Zorbax C3 5 µm, 250 × 9.4 mm semi-preparative column, 4 
mL/min, isocratic 0.01% TFA modifier, isocratic elution of 
90% H2O/MeCN for 5 min, then a gradient elution from 90% 
H2O/MeCN to 40% H2O/MeCN over 15 min, then a 4 min hold 
at 100% MeCN, to yield hymenialdisine (5) (tR = 10.6 min, 7.1 
mg) and 2-bromoaldisine (6) (tR = 13.0, 5.0 mg).  
 
The remainder of the MeOH solubles (37.2 mg) derived from 
the n-BuOH solubles was subjected to HPLC fractionation 
(Agilent Zorbax Eclipse C8 5 µm, 250 × 9.4 mm semi-
preparative column, 4 mL/min, isocratic 0.01% TFA modifier, 
gradient elution from 90% H2O/MeOH to 64% H2O/MeOH 
over 10 min, then from 64% H2O/MeOH to 22% H2O/MeOH 
over 16.4 min, then from 22% H2O/MeOH to 100% MeOH 
over 1.6 min, then a 3 min hold at 100% MeOH, to yield 
hymenialdisine (5) (tR = 10.1 min, 3.0 mg), 2-bromoaldisine (6) 
(tR = 13.2 min, 3.9 mg), callyspongisine D (4) (tR = 15.8 min, 
1.4 mg) and callyspongisine C (3) (tR =21.6 min, 0.9 mg).  
 
The MeOH solubles (168.4 mg) derived from H2O solubles 
were subjected to HPLC fractionation (Agilent Zorbax C3 5 
µm, 250 × 9.4 mm semi-preparative column, 4.2 mL/min, 
isocratic 0.01% TFA modifier, gradient elution from 90% 
H2O/MeOH to 75% H2O/MeOH over 8 min, then from 75% 
H2O/MeOH to 40% H2O/MeOH over 10 min, then from 40% 
H2O/MeOH to 100% MeOH over 2 min, then a 3 min hold at 
100% MeOH, to yield callyspongisine A (1) (tR = 8.3 min, 1.5 
mg), hymenialdisine (5) (tR = 13.4 min, 1.1 mg) and 2-
bromoaldisine (6) (tR = 16.4 min, 0.7 mg). 
 
% yields for 1 (0.41%), 3 (0.49%), 4 (0.38%), 5 (3.1%) and 6 
(2.7%) are calculated as weight-to-weight estimate against the 
crude extract (366.4 mg). 
Characterisation of compounds 
Callyspongisine A (1). Amorphous solid. [α]D
23
 –3.0 (c 0.14, 
MeOH); UV (MeOH) λmax (log ε) 204 (3.96), 236 (3.99), 274 
(3.61) nm; NMR (600 MHz, DMSO-d6) see Table 1 and ESI 
Table S2; HRESI(–)MS m/z 417.9841 [M–H]– (calcd for 
C12H13
79BrN5O5S
–, 417.9826). 
 
Callyspongisine B (2). Amorphous solid. UV (MeOH) λmax (log 
ε) 224 (3.80), 273 (3.56) nm; NMR (600 MHz, DMSO-d6) see 
Table 1 and ESI Table S10; HRESI(–)MS m/z 418.9665 [M–
H]– (calcd for C12H12
79BrN4O6S
–, 418.9666). Insufficient 
quantities of 2 were available to obtain a stable optical rotation 
measurement. 
 
Callyspongisine C (3). [α]D
21
 –10 (c 0.1, EtOH); Amorphous 
solid. UV (MeOH) λmax (log ε) 203 (3.63), 220 (3.45), 274 
(3.64) nm; NMR (600 MHz, DMSO-d6) see Table 1 and ESI 
Table S3; HRESI(+)MS m/z 345.0442 [M+H]+ (calcd for 
C13H18
79BrN2O4
+, 345.0444). 
 
Callyspongisine D (4). [α]D
21
 –13 (c 0.1, EtOH); Amorphous 
solid. UV (MeOH) λmax (log ε) 203 (3.42), 273 (3.33) nm; 
NMR (600 MHz, DMSO-d6) data see Table 1 and ESI Table 
S4; HRESI(+)MS m/z 338.9957 [M+Na]+ (calcd for 
C11H13
79BrN2O4Na
+, 338.9951). 
 
Hymenialdisine (5). A yellow solid. NMR (DMSO-d6, 600 
MHz) data see ESI Table S5; HRESI(+)MS m/z 324.0097 
[M+H]+ (calc. for C11H11BrN5O2
+, 324.0091). 
 
2-Bromoaldisine (6). A yellow oil. NMR (DMSO-d6, 600 
MHz) data see ESI Table S6; HRESI(–)MS m/z 240.9627 [M–
H]– (calc. for C8H6
79BrN2O2
–, 240.9618). 
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